Home

Friday, January 10, 2025 12:30 – 1:00 PM ET CME/CNE/CPE/IPCE Virtual Hypertrophic cardiomyopathy (HCM) is the most common genetic heart disease in the United States, affecting almost 1 in 500 patients, but it can also occur without an identifiable genetic mutation. With new therapies targeting the underlying pathophysiology, approved and on the horizon, it is now a treatable disease with a normal life expectancy. However, to improve patient cardiovascular outcomes, coordination of care amongst the

Read the full article here

Source: events.medscapelive.org

Categories: Dermatology, General Medicine News

Tags: HCM,TeamCare,HFSA2024

Tweets with this article

Medscape Dermatology

🤝 Explore the unique roles of the interprofessional team in HCM care. 💡 Enhance communication, coordination, and teamwork to optimize comprehensive management for patients with HCM. 🌟 Learn more: https://t.co/Q3xQY0178u #HCM #TeamCare #HFSA2024 https://t.co/vcKpyCuPjh

Related Articles

29th Annual Acute Leukemia Forum 2025 | La Jolla, California

Register now and explore groundbreaking advancements in acute leukemia and myelodysplasia treatment at ALF 2025. Stay informed with the latest innovations shaping the future of…

Medscape Dermatology January 8, 2025

VYNE Completes Phase 2b Enrollment for Vitiligo Gel

Repibresib’s localized delivery minimizes systemic exposure while targeting inflammatory pathways, a novel approach for vitiligo management.

Dermatology Times January 7, 2025

Tobacco Smoke Exposure Unlikely to Worsen Atopic Dermatitis in Youth

A comprehensive study finds no significant link between exposure to tobacco smoke and the severity or activity of atopic dermatitis in children and adolescents.

The Dermatologist January 7, 2025

Quoin Pharmaceuticals’ Announces Positive Interim QRX003 Data for Netherton Syndrome

The results showed promising improvements in all endpoints with high patient satisfaction and no safety concerns.

Dermatology Times January 7, 2025

Organic Filter-Based Sunscreens are Safe, Effective, and User-Friendly for Sensitive Skin

After 8 weeks of use, the product showed improvements in skin sensitivity, transepidermal water loss, and skin corneum hydration.

Dermatology Times January 7, 2025

Racial and Ethnic Differences in the Risk of Second Primary Melanoma

This cohort study assesses the incidence of a second melanoma diagnosis after initial diagnosis among racial and ethnic minority populations.

JAMA Dermatology January 7, 2025

Top 5 Articles of the Week: December 29 – January 3

Explore the top headlines of the week including 2025 PDUFA dates, 2024 interview insights, and awareness dates to add to your calendar.

Dermatology Times January 6, 2025

2025 AAD Annual Meeting: Abstract presentations

Find information about submitting and presenting abstracts at the 2025 AAD Annual Meeting.

AADmember January 6, 2025

Impact of Clinical Information on Melanocytic Skin Lesion Pathology Diagnosis

This scoping review examines the impact of clinical information on the histopathologic diagnosis of melanocytic skin lesions.

JAMA Dermatology January 6, 2025

FDA Proposes Mandatory Asbestos Testing for Talc-Containing Cosmetics

The FDA recently proposed a new rule requiring standardized asbestos testing in talc-containing cosmetics to protect consumers from potential harm.

Dermatology Times January 6, 2025